Geode Capital Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-275,892
| Closed | -$4.12M | – | 4959 |
|
|
2022
Q4 | $4.12M | Buy |
275,892
+7,578
| +3% | +$105K | ﹤0.01% | 2761 |
|
|
2022
Q3 | $2.21M | Sell |
268,314
-15,655
| -6% | -$120K | ﹤0.01% | 3053 |
|
|
2022
Q2 | $1.86M | Buy |
283,969
+15,285
| +6% | +$74K | ﹤0.01% | 3138 |
|
|
2022
Q1 | $1.5M | Buy |
268,684
+9,619
| +4% | +$39.6K | ﹤0.01% | 3409 |
|
|
2021
Q4 | $1.22M | Buy |
259,065
+9,096
| +4% | +$56.4K | ﹤0.01% | 3618 |
|
|
2021
Q3 | $1.54M | Buy |
249,969
+4,324
| +2% | +$25.9K | ﹤0.01% | 3473 |
|
|
2021
Q2 | $1.62M | Sell |
245,645
-152,292
| -38% | -$1.05M | ﹤0.01% | 3360 |
|
|
2021
Q1 | $2.91M | Buy |
397,937
+77,262
| +24% | +$667K | ﹤0.01% | 3078 |
|
|
2020
Q4 | $1.85M | Buy |
320,675
+42,904
| +15% | +$246K | ﹤0.01% | 3124 |
|
|
2020
Q3 | $1.65M | Buy |
277,771
+82,745
| +42% | +$409K | ﹤0.01% | 2975 |
|
|
2020
Q2 | $1M | Buy |
195,026
+97,427
| +100% | +$615K | ﹤0.01% | 3135 |
|
|
2020
Q1 | $353K | Sell |
97,599
-2
| -0% | -$10 | ﹤0.01% | 3374 |
|
|
2019
Q4 | $609K | Sell |
97,601
-16,211
| -14% | -$119K | ﹤0.01% | 3441 |
|
|
2019
Q3 | $961K | Sell |
113,812
-491
| -0.4% | -$3.65K | ﹤0.01% | 3250 |
|
|
2019
Q2 | $769K | Sell |
114,303
-29,014
| -20% | -$249K | ﹤0.01% | 3312 |
|
|
2019
Q1 | $1.18M | Buy |
143,317
+3,859
| +3% | +$39.8K | ﹤0.01% | 3095 |
|
|
2018
Q4 | $2.23M | Buy |
139,458
+37,133
| +36% | +$817K | ﹤0.01% | 2717 |
|
|
2018
Q3 | $3.39M | Buy |
102,325
+4,471
| +5% | +$115K | ﹤0.01% | 2605 |
|
|
2018
Q2 | $2.21M | Buy |
97,854
+31,058
| +46% | +$736K | ﹤0.01% | 2799 |
|
|
2018
Q1 | $1.94M | Hold |
66,796
| – | – | ﹤0.01% | 2777 |
|
|
2017
Q4 | $1.86M | Buy |
66,796
+4,062
| +6% | +$126K | ﹤0.01% | 2791 |
|
|
2017
Q3 | $2.29M | Buy |
62,734
+2,773
| +5% | +$85.8K | ﹤0.01% | 2667 |
|
|
2017
Q2 | $1.33M | Buy |
59,961
+28,446
| +90% | +$224K | ﹤0.01% | 2965 |
|
|
2017
Q1 | $185K | Buy |
31,515
+1,187
| +4% | +$8.57K | ﹤0.01% | 3684 |
|
|
2016
Q4 | $163K | Hold |
30,328
| – | – | ﹤0.01% | 3677 |
|
|
2016
Q3 | $269K | Hold |
30,328
| – | – | ﹤0.01% | 3488 |
|
|
2016
Q2 | $291K | Buy |
30,328
+2,105
| +7% | +$20.3K | ﹤0.01% | 3440 |
|
|
2016
Q1 | $259 | Hold |
28,223
| – | – | ﹤0.01% | 3543 |
|
|
2015
Q4 | $355K | Sell |
28,223
-333
| -1% | -$3.96K | ﹤0.01% | 3430 |
|
|
2015
Q3 | $345K | Sell |
28,556
-9,729
| -25% | -$141K | ﹤0.01% | 3410 |
|
|
2015
Q2 | $666K | Buy |
38,285
+10
| +0% | +$180 | ﹤0.01% | 3079 |
|
|
2015
Q1 | $554K | Buy |
38,275
+901
| +2% | +$9.84K | ﹤0.01% | 3153 |
|
|
2014
Q4 | $314K | Buy |
37,374
+31
| +0.1% | +$283 | ﹤0.01% | 3394 |
|
|
2014
Q3 | $414K | Buy |
37,343
+14,934
| +67% | +$190K | ﹤0.01% | 3250 |
|
|
2014
Q2 | $410K | Sell |
22,409
-2,620
| -10% | -$34.1K | ﹤0.01% | 3242 |
|
|
2014
Q1 | $374K | Buy |
25,029
+6,519
| +35% | +$117K | ﹤0.01% | 3272 |
|
|
2013
Q4 | $340K | Buy |
18,510
+21
| +0.1% | +$421 | ﹤0.01% | 3240 |
|
|
2013
Q3 | $383K | Buy |
18,489
+737
| +4% | +$16.9K | ﹤0.01% | 3065 |
|
|
2013
Q2 | $444K | Buy |
+17,752
| New | +$759K | ﹤0.01% | 2942 |
|
Geode Capital Management's AVEO Position: Q1 2023 in Review
Geode Capital Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 275,892 shares — an estimated $4.12M sold.
Geode Capital Management first reported a position in AVEO in Q2 2013 and held it in 39 quarters. The position peaked at $4.12M in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.
- Geode Capital Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Geode Capital Management sold 275,892 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $4.12M.
- Geode Capital Management first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 39 quarters.
- Geode Capital Management's AVEO Pharmaceuticals, Inc. position peaked at $4.12M in Q4 2022.
- 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.
Based on Geode Capital Management's 13F filing for Q1 2023, filed 15 May 2023.